Metronidazole CAS 443-48-1

  • Targeted Anaerobic Efficacy: Selectively acts against anaerobic pathogens by inhibiting bacterial DNA synthesis, thereby inducing cellular degeneration and death.

  • Broad-Spectrum Clinical Application: Effectively manages a diverse array of infections—including respiratory, gastrointestinal, intra-abdominal, dermatological, and central nervous system infections—precipitated by anaerobic bacteria.

  • Established Gold Standard: Recognized by the World Health Organization (WHO) since 1978 as a primary, frontline therapeutic intervention for oral and systemic anaerobic infections.

  • Versatile Therapeutic Utility: Extensively deployed for both the clinical treatment and prophylactic management of severe anaerobic complications, such as purulent pericarditis and septicemia.

WhatsApp
Product Details

Classified as a nitroimidazole-class antimicrobial agent also known as flagyl, metronidazole demonstrates robust efficacy against anaerobic microorganisms. Its enzymatically reduced metabolites within the human body exert potent anti-anaerobic activity by impairing bacterial DNA synthesis, thereby arresting microbial proliferation and inducing cell death. This targeted agent successfully addresses a broad spectrum of anaerobic pathogens, including Bacteroides fragilis,Fusobacterium species (noted for their distinctive tapered, spindle-shaped morphology),Clostridium tetani,Peptococcus,Peptostreptococcus, and Giardia.

Metronidazole CAS#443-48-1

Originally developed to treat trichomoniasis with exceptional clinical success, this agent was subsequently found to be highly effective against oral anaerobic infections. Acknowledged by the World Health Organization in 1978 as the gold-standard therapeutic intervention for anaerobic pathogens, it has achieved widespread clinical adoption in the management of oral anaerobic conditions. Furthermore, in standard medical practice, it is routinely utilized for both the prophylaxis and treatment of anaerobic infections involving the respiratory tract, gastrointestinal system, abdomino-pelvic cavities, dermatological tissues, soft tissues, musculoskeletal systems, as well as critical systemic pathologies such as purulent pericarditis, septicemia, and central nervous system infections.

Metronidazole CAS#443-48-1

Melting point 159-161 °C (lit.)
Boiling point 301.12°C (rough estimate)
density 1.3994 (rough estimate)
refractive index 1.5800 (estimate)
Fp 9℃
storage temp. 2-8°C
solubility acetic acid: 0.1 M, clear, faintly yellow
form crystalline
pkapKa 2.62(H2O,t =25±0.2,Iundefined) (Uncertain)
color white to light yellow
Water Solubility <0.1 g/100 mL at 20 ºC
Merck 146157
BRN 611683
BCS Class1,3
Stability:Stable. Incompatible with strong oxidizing agents.
InChIKeyVAOCPAMSLUNLGC-UHFFFAOYSA-N
LogP-0.02
IARC2B (Vol. 13, Sup 7) 1987
NIST Chemistry ReferenceMetronidazole(443-48-1)
EPA Substance Registry SystemMetronidazole (443-48-1)

Safety Information

Hazard Codes Xn
Risk Statements 40-46-45-39/23/24/25-23/24/25-11
Safety Statements 36/37-45-53-16-7
WGK Germany 3
RTECS NI5600000
F 8
HS Code 29332990
Hazardous Substances Data443-48-1(Hazardous Substances Data)

Metronidazole CAS#443-48-1

WhatsApp